Development of triple mutant T790M/C797S allosteric EGFR inhibitors: a computational approach.
The mutations concerned with non-small cell lung cancer involving epidermal growth factor receptor of tyrosine kinase family have primarily targeted. EGFR inhibitors binding allosterically to C797S mutant EGFR enzyme have been developed. Here, database building, library screening performing R-group enumeration and scaffold hopping technique for increasing the EGFR binding affinity of compounds have been carried out. Virtual screening was performed subjecting to HTVS, SP and XP docking protocol along with its relative binding free energy calculations. Molecular docking studies provided the information about binding pockets and interactions of molecules on mutant (PDB: 5D41) as well as wild type (PDB: 4I23) EGFR enzyme. This was supported with ADMET and molecular simulation studies. On the basis of glide score and protein-ligand interactions, highest scoring molecule was selected for molecular dynamic simulation providing a complete insight into the conformational stability. The virtually screened molecules can act as potential EGFR inhibitors in the management of drug resistance. Communicated by Ramaswamy H. Sarma.
['Karnik|Kshipra S|KS|', 'Sarkate|Aniket P|AP|', 'Lokwani|Deepak K|DK|', 'Narula|Ishudeep S|IS|', 'Burra|Prasad V L S|PVLS|', 'Wakte|Pravin S|PS|0000-0002-8118-2963']
D002289:Carcinoma, Non-Small-Cell Lung D019008:Drug Resistance, Neoplasm D066246:ErbB Receptors D006801:Humans D008175:Lung Neoplasms D062105:Molecular Docking Simulation D009154:Mutation D047428:Protein Kinase Inhibitors
allosteric EGFR Non-small cell lung cancer virtual screening molecular docking molecular dynamics simulations library generation